Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2/3 Study of ALX148 (evorpacept) in Advanced HER2-Overexpressing Gastric/GEJ Adenocarcinoma
2021-001008-14Phase 2Active
- Sponsor
- ALX Oncology
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of evorpacept in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gastric cancer (GC) and 1 more, sponsored by ALX Oncology. Primary endpoint: Primary endpoints (Phase 2). Started Jul 2021; status: active.
02
Drugs
evorpacept
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2021-001008-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001008-14.